- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01477437
Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia
Development and Evaluation of an Internet-based Educational Program to Promote Self- Management for Teens With Hemophilia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overall aim of this program of research is to develop and evaluate the "Teens Taking Charge: Managing Hemophilia Online" Internet intervention that will help adolescents with hemophilia to better understand and manage their disease independently. This program is modeled after Dr. Stinson's similar successful internet self-management program developed for youth with arthritis.
This program is being developed and evaluated using a sequential, phased approach. The first phase of this project has determined the self-management and transitional care needs of adolescents with hemophilia. Currently, in Phase 2A, we are developing the website with the content based on the findings from the Phase 1 needs assessment. We propose the current study to conduct usability testing (Phase 2B) to make sure it is easy to use and understand, and is efficient and satisfying to complete. Subsequently, we will assess the feasibility of the program and the outcomes from the use of the site in a randomized controlled trial (RCT) pilot study (Phase 3). This will enable us to determine an appropriate sample size for the future mixed controlled trial. Phases 2B and 3 are the focus of this proposal. Phase 4 will be a multicentre randomized controlled trial to assess outcomes for teens that complete the intervention as compared to those of an attention control group. This randomized controlled trial controlled trial will include all interested pediatric hemophilia treatment centres across Canada.
We hypothesize that adolescents with hemophilia who complete the "Teens Taking Charge: Managing Hemophilia Online" Internet intervention will demonstrate: increased hemophilia specific knowledge, increased self-efficacy, improved health-related quality of life (HRQL) and decreased stress prior to transition to adult health care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X8
- The Hospital for Sick Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 13-18
- diagnosis of mild, moderate or severe hemophilia A or B
- be able to speak and read English or French.
- must have access to the Internet at home
Exclusion Criteria
- cognitive impairments
- haematologist feels that they have a significant medical or psychiatric condition that will impact their participation
- don't have access to the internet.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control group
|
|
EXPERIMENTAL: Intervention (experimental) Group
|
The content will be delivered on a password-protected website, as part of the "About Kids Health" interface developed and maintained at the Hospital for Sick Children, Toronto, Canada.
The website has been developed as eight discrete educational modules for adolescents.
Each module takes approximately 30 to 45 minutes to complete.
Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials.
Content has been written in English and will be translated into French prior to program launch.
The format is geared towards adolescents and includes narratives with video components and interactive illustrations.
In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-specific knowledge gained
Time Frame: Baseline
|
assessed by pre and post-assessment of the "Hemophilia Knowledge Questionnaire".
This novel tool will be developed by investigators based on core content deemed important by hemophilia care providers and be reviewed for face validity by the Hemophilia Care Teams in both study centers and by a National panel of reviewers prior to administration.
|
Baseline
|
Disease-specific knowledge gained
Time Frame: Immediately post-intervention - 8 weeks
|
assessed by pre and post-assessment of the "Hemophilia Knowledge Questionnaire".
This novel tool will be developed by investigators based on core content deemed important by hemophilia care providers and be reviewed for face validity by the Hemophilia Care Teams in both study centers and by a National panel of reviewers prior to administration.
|
Immediately post-intervention - 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health-related Quality of Life (HRQL)
Time Frame: Baseline and immediately post-intervention - 8 weeks
|
Assessed pre and post intervention using the CHOK-LAT (Canadian Hemophilia Outcomes- Kids' Life Assessment Tool).
This 35 item tool was developed at the Hospital for Sick Children and has been shown to be reliable and valid in assessing HRQL in children and adolescents with hemophila
|
Baseline and immediately post-intervention - 8 weeks
|
Self-efficacy (Generalised Self-Efficacy-Sherer Scale)
Time Frame: Baseline and immediately post-intervention - 8 weeks
|
This tool measures self efficacy.
The 17-item scale was originally developed by Sherer and modified by Bosscher and Smit to include 12 items in three sub-scales (initiative, effort and persistence).
This scale has been validated and found to be reliable in diverse populations.
Although not validated specifically in adolescents, it has been used to study this population.
|
Baseline and immediately post-intervention - 8 weeks
|
Preparedness for Transition
Time Frame: Baseline and immediately post-intervention - 8 weeks
|
Measured using questionnaire developed by the John Hopkins Adult Cystic Fibrosis Program in a survey analyzing patient attitudes towards transition.
The questions from this questionnaire have already been used in transition studies focused adolescents with hemophilia
|
Baseline and immediately post-intervention - 8 weeks
|
Impact of the program
Time Frame: Baseline and immediately post-intervention - 8 weeks
|
Will be measured in the intervention group only using the HEI-Q (Health Information Impact Questionnaire)
|
Baseline and immediately post-intervention - 8 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000023483
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia A
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
GWT-TUD GmbHHannover Medical School; Hoffmann-La RocheCompleted
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
Hoffmann-La RocheActive, not recruitingSevere Hemophilia A | Moderate Hemophilia ABrazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
-
JW PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A Without InhibitorKorea, Republic of
-
PfizerCompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
BioMarin PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A With Anti Factor VIIIUnited States, United Kingdom, Taiwan, Israel, Korea, Republic of, South Africa, Brazil, Italy, Germany
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
BayerCompletedHemophilia A; Hemophilia BIsrael
Clinical Trials on Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention
-
The Hospital for Sick ChildrenDalhousie University; IWK Health Centre; Provincial Health Services Authority; The... and other collaboratorsCompletedJuvenile Idiopathic ArthritisCanada
-
The Hospital for Sick ChildrenMcGill University; University of Alberta; McMaster University; Hamilton Health... and other collaboratorsCompleted
-
The Hospital for Sick ChildrenCompletedArthritis, Juvenile IdiopathicCanada
-
Leiden UniversityLeiden University Medical CenterCompletedArthritis | Joint Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Osteoarthritis